RxDoctor Payments Data

Chris Kolyvas, MD

Cardiovascular Disease · New Lenox, ILNPI 1932157302

Payments from drug & device makers

$1,966in general payments, 2019–2025

Across 87 payments — averaging $22.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Livanova USA, Inc.$490
  • Merck$172
  • Novartis$150
  • Sanofi-aventis U.S. LLC$137
  • Abiomed$135
  • Abbott$129
  • plus $753 from 20 others

What the payments were for

  • Travel & lodging$49025%
  • Food & beverage$1,44173%
  • Education$362%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,966 in reported general payments places this provider in the 50th percentile of 932 cardiovascular disease providers in Illinois.

See all cardiovascular disease providers in Illinois

Medicare billing

Part B allowed, 2024
$417,845
Medicare patients
1,305
Services billed
4,355

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban403$470,594
EntrestoSacubitril/Valsartan128$182,638
XareltoRivaroxaban150$160,656
BrilintaTicagrelor36$32,729
JardianceEmpagliflozin30$29,075
MultaqDronedarone Hcl13$28,936
Repatha SureclickEvolocumab25$27,171
FarxigaDapagliflozin Propanediol18$14,564
LivaloPitavastatin Calcium21$11,607
Metoprolol Succinate524$10,124
Carvedilol ErCarvedilol Phosphate15$9,148
Atorvastatin Calcium758$8,403
ClopidogrelClopidogrel Bisulfate523$7,831
Carvedilol408$4,351
Rosuvastatin Calcium286$4,130

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$93$470,594403 claims
NovartisEntresto$150$182,638128 claims
Johnson & JohnsonXarelto$55$160,656150 claims
AstraZenecaBrilinta, Farxiga$28$47,29354 claims
Boehringer IngelheimJardiance$18$29,07530 claims
Sanofi-aventis U.S. LLCMultaq$137$28,93613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 932 cardiovascular disease providers in Illinois.

Other cardiovascular disease in New Lenox

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →